Connection

Richard Mills to Adjuvants, Immunologic

Back to Details
This is a "connection" page, showing publications Richard Mills has written about Adjuvants, Immunologic.
Richard Mills
Connection Strength
0.031
Adjuvants, Immunologic
  1. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial. Vaccine. 2016 Apr 27; 34(19):2170-8.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.